Tae-Sung Koo

List of Publications by Year
in descending order

41 papers	442 citations	686830 13 h-index	794141 19 g-index
41 all docs	41 docs citations	41 times ranked	629 citing authors

#	Article	IF	Citations
1	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors. Bioorganic and Medicinal Chemistry, 2022, 53, 116550.	1.4	4
2	Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies. Molecules, 2022, 27, 1977.	1.7	26
3	Design and Synthesis of a Novel 4-aryl-N-(2-alkoxythieno) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 667 Td ([2,3-b]pyrazine-3-yl)- Cancer through G2/M Arrest. Pharmaceuticals, 2022, 15, 502.	1.7	3
4	The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers. Pharmaceutics, 2021, 13, 344.	2.0	12
5	Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. Pharmaceutics, 2021, 13, 373.	2.0	0
6	Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122862.	1.2	11
7	Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs. BMC Veterinary Research, 2021, 17, 295.	0.7	1
8	Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112987.	1.4	4
9	A highly sensitive fluorescent probe that quantifies transthyretin in human plasma as an early diagnostic tool of Alzheimer's disease. Chemical Communications, 2019, 55, 10424-10427.	2.2	15
10	Effects of formulation types on pharmacodynamics of warfarin in patients with cerebral infarction and dysphagia . Clinical Pharmacology: Advances and Applications, 2019, Volume 11, 51-56.	0.8	0
11	Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. Journal of Veterinary Internal Medicine, 2019, 33, 531-535.	0.6	7
12	Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease. Experimental Eye Research, 2019, 180, 8-17.	1.2	21
13	Liquid chromatographyâ€“tandem mass spectrometry of recombinant human extracellular superoxide dismutase (rhSOD3) in mouse plasma and its application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 590-597.	1.4	3
14	Enhanced Solubility, In-Vitro Dissolution and Lipase Inhibition of a Self-Nanoemulsifying Drug Delivery System Containing Orlistat. Journal of Nanoscience and Nanotechnology, 2019, 19, 634-639.	0.9	5
15	Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2018, 148, 397-409.	2.6	9
16	Effects of Angelica gigas extract on the oral pharmacokinetics of gefitinib in rats. Journal of Pharmaceutical Investigation, 2018, 48, 295-300.	2.7	2
17	Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats. Xenobiotica, 2018, 48, 831-838.	0.5	1
18	Development of a liquid chromatography-tandem mass spectrometry method for assaying cenobamate in rat plasma. Journal of Liquid Chromatography and Related Technologies, 2018, 41, 992-997.	0.5	7

#	Article	IF	Citations
19	Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance. International Journal of Nanomedicine, 2018, Volume 13, 7095-7106.	3.3	20
20	Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs. BMC Veterinary Research, 2018, 14, 291.	0.7	6
21	Development and Evaluation of Raloxifene-Hydrochloride-Loaded Supersaturatable SMEDDS Containing an Acidifier. Pharmaceutics, 2018, 10, 78.	2.0	20
22	Development and validation of a liquid chromatographyâ€“tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats. Journal of Pharmaceutical and Biomedical Analysis, 2017, 137, 90-95.	1.4	8
23	A validated HPLCâ€“MS/MS method for the quantification of supinoxin in rat plasma and its application to pharmacokinetic study. Acta Chromatographica, 2017, 29, 463-468.	0.7	2
24	Development of a LCâ€“MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 123-127.	1.2	0
25	Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs. Regulatory Toxicology and Pharmacology, 2016, 81, 387-396.	1.3	10
26	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors. European Journal of Medicinal Chemistry, 2016, 123, 777-787.	2.6	13
27	Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Archives of Pharmacal Research, 2015, 38, 2076-2082.	2.7	21
28	Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3947-3952.	1.0	11
29	Hair-Growth-Promoting Effect of Conditioned Medium of High Integrin Î±6 and Low CD 71 (Î±6bri/CD71dim) Positive Keratinocyte Cells. International Journal of Molecular Sciences, 2015, 16, 4379-4391.	1.8	18
30	Simultaneous quantification of methylene blue and its major metabolite, azure B, in plasma by LCâ€MS/MS and its application for a pharmacokinetic study. Biomedical Chromatography, 2014, 28, 518-524.	0.8	18
31	Quantitative determination of enzalutamide, an antiâ€prostate cancer drug, in rat plasma using liquid chromatographyâ€“tandem mass spectrometry, and its application to a pharmacokinetic study. Biomedical Chromatography, 2014, 28, 1112-1117.	0.8	25
32	Discovery of non-LBD inhibitor for androgen receptor by structure-guide design. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3887-3890.	1.0	6
33	Liquid chromatographyâ€“tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic study. Biomedical Chromatography, 2012, 26, 371-376.	0.8	18
34	Functional Impairment of Rat Taurine Transporter by Activation of Nitrogen Oxide through Superoxide. Drug Metabolism and Pharmacokinetics, 2012, 27, 286-293.	1.1	3
35	A Sensitive and Selective LC-MS Method for the Determination of Lurasidone in Rat Plasma, Bile, and Urine. Chromatographia, 2012, 75, 1117-1128.	0.7	12
36	Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica, 2011, 41, 1100-1107.	0.5	25

#	Article	IF	Citations
37	Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. Archives of Pharmacal Research, 2011, 34, 2059-2064.	2.7	26
38	Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomedical Chromatography, 2011, 25, 1389-1394.	0.8	24
39	Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. Journal of Pharmacy and Pharmacology, 2010, 58, 837-846.	1.2	5
40	Quantification of clotiazepam in human plasma by gas chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 834, 128-133.	1.2	5
41	Comparison of Pharmacokinetics of Loxoprofen and its Active Metabolites After an Intravenous, Intramuscular, and Oral Administration of Loxoprofen in Rats: Evidence for Extrahepatic Metabolism. Journal of Pharmaceutical Sciences, 2005, 94, 2187-2197.	1.6	15